What is Imaginostics?
Imaginostics operates at the intersection of advanced medical imaging and quantitative diagnostics. The company specializes in non-invasive solutions that utilize breakthrough biomarkers to enhance the clinical utility of standard MRI scanners. By enabling the visualization of complex vasculature and providing precise health assessments, Imaginostics facilitates early detection and monitoring of conditions in neuroscience, oncology, and cardiology.
The company's technology is designed for seamless compatibility with existing hospital hardware, reducing the barrier to entry for clinical adoption. Through its focus on safe, effective, and scalable diagnostic tools, Imaginostics is actively bridging the gap between academic research and bedside patient care, fostering partnerships that drive innovation in disease management.
How much funding has Imaginostics raised?
Imaginostics has raised a total of $6.6M across 4 funding rounds:
Multiple Rounds
$6.6M
Stock/Share Issuance (2026): $5.4M, investors not publicly disclosed
Stock/Share Issuance (2026): $500K, investors not publicly disclosed
Stock/Share Issuance (2026): $726K, investors not publicly disclosed
Stock/Share Issuance (2026): $40K, investors not publicly disclosed
Key Investors in Imaginostics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Imaginostics?
With the recent infusion of capital, Imaginostics is poised to transition into a phase of rapid commercial expansion and clinical validation. The strategic roadmap includes deepening its footprint in oncology and neuroscience research, where the demand for non-invasive, high-resolution diagnostic data is at an all-time high. Furthermore, the company is expected to prioritize the development of its partnership ecosystem, engaging with academic investigators and major healthcare providers to standardize its imaging protocols.
Looking ahead, the firm will likely focus on regulatory milestones and the integration of its biomarkers into routine clinical workflows. By maintaining a focus on data-driven health outcomes, Imaginostics is well-positioned to redefine the standard of care in diagnostic imaging, ensuring that its technology remains a cornerstone of modern medical practice.
